|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001613,
umls-concept:C0007776,
umls-concept:C0022655,
umls-concept:C0030685,
umls-concept:C0034693,
umls-concept:C0204695,
umls-concept:C0205099,
umls-concept:C0243076,
umls-concept:C0378126,
umls-concept:C0391871,
umls-concept:C0392747,
umls-concept:C0439849,
umls-concept:C0443172,
umls-concept:C0599682,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1515655,
umls-concept:C1963578,
umls-concept:C2827063
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-26
|
|
pubmed:abstractText |
Cannabinoid type 1 (CB(1)) receptor antagonists are reportedly effective in reducing food intake both preclinically and clinically. This may be due in part to their effects on monoamine release in the brain. The level of central CB(1) receptor occupancy underlying these neurobiological effects is unclear.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0033-3158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
184
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
26-35
|
|
pubmed:dateRevised |
2007-10-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16328376-Animals,
pubmed-meshheading:16328376-Dopamine,
pubmed-meshheading:16328376-Feeding Behavior,
pubmed-meshheading:16328376-Frontal Lobe,
pubmed-meshheading:16328376-Male,
pubmed-meshheading:16328376-Microdialysis,
pubmed-meshheading:16328376-Norepinephrine,
pubmed-meshheading:16328376-Piperidines,
pubmed-meshheading:16328376-Prefrontal Cortex,
pubmed-meshheading:16328376-Pyrazoles,
pubmed-meshheading:16328376-Radioligand Assay,
pubmed-meshheading:16328376-Rats,
pubmed-meshheading:16328376-Rats, Wistar,
pubmed-meshheading:16328376-Receptor, Cannabinoid, CB1,
pubmed-meshheading:16328376-Sulfonamides
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285-0510, USA.
|
|
pubmed:publicationType |
Journal Article
|
